Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global ...

Genentech is planning a massive overhaul of its 207-acre South San Francisco campus that could cost between $3B and $5B by the time the multiphase project is complete, according to the San Francisco ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

News & Observer readers comments on NC's business ranking, speeding in a Raleigh area, a gun bill, flooding, Thom Tillis, ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Patients with neuro conditions are asked to consult with their neurologist, above all else, before seeking out therapeutic ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

The story behind the development of immune checkpoint inhibitors, fulfilling the promise of cancer immunotherapy ...

Analytical chemistry researchers at the University of Amsterdam's Van 't Hoff Institute for Molecular Sciences (HIMS) have ...

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement (updated August 13, 2024) ...

Perfuse Therapeutics' drug-device PER-001 shows promise in treating glaucoma and diabetic retinopathy, potentially restoring vision in patients.